Causes and Consequences of Oxidative Stress in Neurodegenerative Diseases

  • Domenico Praticò
Part of the Research and Perspectives in Alzheimer's Disease book series (ALZHEIMER)


As people worldwide live to an older age, dementia, whose best-known risk factor is aging, has become a serious growing public health problem. While Alzheimer's disease (AD) is the most frequent cause of dementia, other progressive neurodegenerative disorders can be responsible for it. For these reasons, they are grouped as non-AD dementias. There is evidence that reactive oxygen species-mediated reactions, particularly of neuronal lipids, are present in brains affected by both types of dementing disorders. Traditional views have claimed that oxidative-mediated brain injury in these diseases is merely the result of the neurodegenerative processes. While numerous investigations have shown that oxidative stress is increased in AD, conflicting results exist for the heterogeneous group of non-AD dementias. The availability of specific and sensitive markers to monitor in vivo oxidative stress, in combination with studies performed in living patients, are helping us to elucidate these issues. This paper summarizes some of the most recent research on the relevance of oxidative stress and lipid peroxidation in AD and non-AD dementias. The evidence accumulated so far clearly indicates that oxidative stress is an early and specificaspect of AD pathogenesis but not of the pathogenesis of other dementias. This new concept implies that this phenomenon is not a general and common pathway of the neurodegenerative process, but it may play a more specific and important role in AD than in non-AD dementias.


Mild Cognitive Impairment Progressive Supranuclear Palsy Frontotemporal Dementia Progressive Supranuclear Palsy Mild Cognitive Impairment Subject 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albers DS, Augood SJ, Park LCH, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JPG, Gibson GE, Beal FM (2000) Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mithocondrial impairment. J Neurochem 72:878–881.CrossRefGoogle Scholar
  2. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Aß42 as diagnostic markers for Alzheimer's disease. Arch Neurol 58:373–379.CrossRefPubMedGoogle Scholar
  3. Arnold SE (2000) Cellular and molecular pathology of the frontal dementias. In: Clark CVM, Trojanowski JQ (eds.) Neurodegenerative dementias: clinical features and pathological mechanisms. New York, NY; McGraw-Hill, pp..291–301.Google Scholar
  4. Balazs L, Leon M (1994) Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 19: 1131–1137.CrossRefPubMedGoogle Scholar
  5. Bourdel-Marchyasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reigner B, Emeriau JP, Rainfray M (2001) Antioxidant defenses and oxidative markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30:235–241.CrossRefPubMedGoogle Scholar
  6. Castellani RJ, Smith MA, Richey PL, Kalaria R, Gambetti P, Perry G (1995) Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 696:268–271.CrossRefPubMedGoogle Scholar
  7. Christen Y (2000) Oxidative stress and Alzheimer's disease. Am J Clin Nutr 71:621S–629S.PubMedGoogle Scholar
  8. Clark CM (2000) Clinical manifestations and diagnostic evaluation of patients with Alzheimer's disease. In: Clark CM, Trojanowski JQ (eds) Neurodegenerative dementias: clinical features and pathological mechanisms. New York, McGraw-Hill, pp. 95–114.Google Scholar
  9. Coyle JT, Oster-Granite ML, Gearhart JD (1986) The neurobiologic consequences of Down syndrome. Brain Res Bull 16:773–787.CrossRefPubMedGoogle Scholar
  10. Floyd RA (1999). Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236–245.CrossRefPubMedGoogle Scholar
  11. Gerst JL, Siedlak SL, Numonura A, Castellani R, Perry G, Smith MA (1999) Role of oxidative stress in frontotemporal dementia. Dement Geriatr Cogn Disord 10(S):85–87.CrossRefPubMedGoogle Scholar
  12. Grossman M, Farmer J, Leight S, Work M, Moore P, van Deerlin V, Praticò D, Clark CM, Coslett HB, Chatterjee A, Trojanowski JQ, Lee VM-Y (2004) Cerebrospinal fluid tau is reduced in frontotemporal dementia and corticobasal degeneration. Ann Neurol, submitted.Google Scholar
  13. Halliwell B, Gutteridge JMC (1999). Free radicals in biology and medicine. 3rd Ed. Oxford: Oxford University Press.Google Scholar
  14. Harman D (1956) Aging: a theory based on free radicals and radiation chemistry. J Gerontol 11:298–300.PubMedGoogle Scholar
  15. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G (1989) Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35: 275–282.PubMedGoogle Scholar
  16. Kim KM, Jung BH, Paeng K-J, Kim I, Chung BC (2004) Increased urinary F2-isoprostanes levels in the patients with Alzheimer's disease. Brain Res Bull 64:47–51.CrossRefPubMedGoogle Scholar
  17. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457–461.CrossRefPubMedGoogle Scholar
  18. Mann DA, South PW, Snowden JS, Neary D (1993) Dementia of the frontal lobe type-neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiat 56: 605–614.PubMedGoogle Scholar
  19. Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33–36.CrossRefPubMedGoogle Scholar
  20. McKhann GM, Grossman M, Albert MS, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of work group on frontotemporal dementia and Pick's disease. Ann Neurol 58:1803–1809.Google Scholar
  21. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ (1997) 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 56:866–871.PubMedGoogle Scholar
  22. Nanomura A, Perry G, Aliev G, Hirai K, Takeda A, Balarj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol 60:759–767.PubMedGoogle Scholar
  23. Odetti P, Garibaldi S, Norese R, Angelini G, Marinelli L, Valentini S, Menini S, Traverso N, Zaccheo D, Siedlak S, Perry G, Smith MA, Tabaton M (2000) Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropath Exp Neurol 59:393–397.PubMedGoogle Scholar
  24. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Robins PV, Ritchie K, Rossor M, Thal L, Winbland B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992.CrossRefPubMedGoogle Scholar
  25. Praticò D (2001) Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 63:563–567.CrossRefGoogle Scholar
  26. Praticò D (2002) Lipid peroxidation and the aging process. Sci Aging Knowledge Environ. Dec 18, 2002 (50): re5.Google Scholar
  27. Praticò D, Delanty N (2000) Oxidative injury in Diseases of the Central Nervous System: Focus on Alzheimer's disease. Am J Med 109:577–585.CrossRefPubMedGoogle Scholar
  28. Praticò D, Sung S (2004) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alz Dis 6:171–175.Google Scholar
  29. Praticò D, Lee V M-Y, Trojanowski JQ, Rokach J, FitzGerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation in vivo. FASEB J 12:177–178.Google Scholar
  30. Praticò D, Clark CM, Lee V MY, Trojanowski JQ, Rokach J, FitzGerald GA (2000a) Increased 8,12-iso-iPF-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809–812.CrossRefPubMedGoogle Scholar
  31. Praticò D, Iuliano L, Amerio G, Rokack J, Sabatino F, Violi F (2000b) Down's syndrome is associated with increased 8,12-iso-iPF-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 48:795–798.CrossRefPubMedGoogle Scholar
  32. Praticò D, Lawson JA, Rokach J, FitzGerald GA (2001) The isoprostanes in biology and medicine. Trends Endocrinol. Metab. 12:243–247.CrossRefPubMedGoogle Scholar
  33. Praticò D, Clark CM, Liun F, Lee V MY, Trojanowski JQ (2002) Increase of oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch Neurol 59:972–976.CrossRefPubMedGoogle Scholar
  34. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24:915–919.CrossRefPubMedGoogle Scholar
  35. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502:139–144.PubMedGoogle Scholar
  36. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55: 342–345.PubMedGoogle Scholar
  37. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA (2001) Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54:565–568.CrossRefPubMedGoogle Scholar
  38. Yao Y, Zhukareva V, Clark CM, Rokach J, Lee VM-Y, Trojanowski JQ, Praticò D (2003) Enhanced brain levels of 8,12-iso-iPF-VI differentiate AD from frontotemporal dementia. Neurology 61:475–478.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Domenico Praticò
    • 1
  1. 1.Center For Experimental Therapeutics, Department of PharmacologyUniversity of Pennsylvania, School of MedicinePhiladelphia

Personalised recommendations